Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Avila Presents Preclinical Data On Two Novel, Orally-Available Protease Inhibitors, A
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2140127" data-attributes="member: 124445"><p>Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus (HCV) protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics. New data on both drugs were presented today at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)...<a href="http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/4zwTJs24P8Q" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/4zwTJs24P8Q/3Bry" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2140127, member: 124445"] Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus (HCV) protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics. New data on both drugs were presented today at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)...[URL="http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/0/da"][IMG]http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/1/da"][IMG]http://feedads.g.doubleclick.net/~a/m5hITpIv8LbRlEJLZF8Rd_s8zBQ/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/4zwTJs24P8Q[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/4zwTJs24P8Q/3Bry]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top